Dai Ichi Life Insurance Company, LTD Bei Gene, Ltd. Transaction History

Dai Ichi Life Insurance Company, LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $301,224 - $550,320	2,400 New	2,400 $527,000
Q2 2022 Aug 12, 2022	SELL	$121.11 - $216.05 $84,777 - $151,235	-700 Reduced 33.33%	1,400 $227,000
Q1 2022 May 13, 2022	SELL	$146.52 - $269.56 $102,564 - $188,692	-700 Reduced 25.0%	2,100 $396,000
Q2 2021 Aug 13, 2021	SELL	$292.75 - $367.01 $58,550 - $73,402	-200 Reduced 6.67%	2,800 $961,000
Q1 2021 May 13, 2021	SELL	$260.64 - $382.12 $130,320 - $191,060	-500 Reduced 14.29%	3,000 $1.04 Million
Q4 2020 Feb 11, 2021	SELL	$221.31 - $316.61 $330,194 - $472,382	-1,492 Reduced 29.89%	3,500 $904,000
Q3 2020 Nov 12, 2020	SELL	$189.18 - $286.44 $10,026 - $15,181	-53 Reduced 1.05%	4,992 $1.43 Million
Q2 2020 Aug 12, 2020	SELL	$123.9 - $195.41 $29,240 - $46,116	-236 Reduced 4.47%	5,045 $950,000
Q1 2020 May 08, 2020	BUY	$121.84 - $173.19 $29,241 - $41,565	240 Added 4.76%	5,281 $650,000
Q4 2019 Feb 13, 2020	BUY	$115.78 - $208.34 $583,646 - $1.05 Million	5,041 New	5,041 $836,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Dai Ichi Life Insurance Company, LTD, based on Form 13F filings with the SEC.

Stay updated on Dai Ichi Life Insurance Company, LTD with notifications on news.